Actelion (now Janssen Pulmonary Hypertension) Risk Report

⚖️ Legal & Regulatory

Actelion (now Janssen Pulmonary Hypertension) has faced several legal and regulatory challenges over the years, affecting its business operations and potentially its reputation. The company has been involved in lawsuits and regulatory penalties that have had financial implications.

• Actelion was involved in a patent suit with Lannett over copies of Uptravi, which resulted in a settlement 🗓 January 23, 2025.
• The company agreed to pay $360 million as part of a federal probe into payments to charity 🗓 December 6, 2018.
• Actelion faced legal scrutiny when Uptravi, one of its key medications, was under review following the death of five patients in France 🗓 February 14, 2017.

🏗️ Operational & Business Continuity

Operational risks have been a critical aspect of Actelion's business landscape. Some strategic decisions and unforeseen events have tested the company's operational resilience.

• A review of Uptravi was prompted by patient deaths, causing operational disruptions as the European Medicines Agency conducted their evaluations 🗓 February 14, 2017.
• Actelion had to defend its strategic operations publicly in response to various challenges, highlighting its intention to maintain independence while discussions of potential acquisitions were ongoing 🗓 December 2, 2016.

📜 Innovation & R&D

Actelion has actively engaged in innovation and research, positioning itself to advance in pharmaceutical treatments, particularly in pulmonary arterial hypertension (PAH).

• In a strategic collaboration, Actelion announced a partnership with Third Pole Therapeutics to explore inhaled nitric oxide therapies 🗓 March 26, 2019.
• The company discovered new PDGFR inhibitors, signaling ongoing research efforts in the competitive pharmaceutical landscape 🗓 February 27, 2023.